Advertisement
BIO vs IRMD
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a Hold and IRMD is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 2 FA rating(s) are green whileIRMD’s FA Score has 2 green FA rating(s).
- BIO’s FA Score: 2 green, 3 red.
- IRMD’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 6 TA indicator(s) are bullish while IRMD’s TA Score has 4 bullish TA indicator(s).
- BIO’s TA Score: 6 bullish, 4 bearish.
- IRMD’s TA Score: 4 bullish, 4 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а +4.42% price change this week, while IRMD (@Medical/Nursing Services) price change was +4.07% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +0.30%. For the same industry, the average monthly price growth was +4.72%, and the average quarterly price growth was +15.64%.
Reported Earning Dates
BIO is expected to report earnings on Oct 29, 2025.
IRMD is expected to report earnings on Oct 31, 2025.
Industries' Descriptions
@Medical/Nursing Services (+0.30% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| BIO | IRMD | BIO / IRMD | |
| Capitalization | 8.92B | 998M | 893% |
| EBITDA | 656M | 24.6M | 2,667% |
| Gain YTD | 2.317 | 42.546 | 5% |
| P/E Ratio | 30.31 | 48.74 | 62% |
| Revenue | 2.55B | 77.6M | 3,291% |
| Total Cash | 1.37B | 53M | 2,592% |
| Total Debt | 1.41B | 0 | - |
BIO | IRMD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 28 | 25 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 82 Overvalued | 59 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 17 | |
SMR RATING 1..100 | 86 | 40 | |
PRICE GROWTH RATING 1..100 | 9 | 39 | |
P/E GROWTH RATING 1..100 | 30 | 16 | |
SEASONALITY SCORE 1..100 | 50 | 10 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IRMD's Valuation (59) in the Medical Specialties industry is in the same range as BIO (82). This means that IRMD’s stock grew similarly to BIO’s over the last 12 months.
IRMD's Profit vs Risk Rating (17) in the Medical Specialties industry is significantly better than the same rating for BIO (100). This means that IRMD’s stock grew significantly faster than BIO’s over the last 12 months.
IRMD's SMR Rating (40) in the Medical Specialties industry is somewhat better than the same rating for BIO (86). This means that IRMD’s stock grew somewhat faster than BIO’s over the last 12 months.
BIO's Price Growth Rating (9) in the Medical Specialties industry is in the same range as IRMD (39). This means that BIO’s stock grew similarly to IRMD’s over the last 12 months.
IRMD's P/E Growth Rating (16) in the Medical Specialties industry is in the same range as BIO (30). This means that IRMD’s stock grew similarly to BIO’s over the last 12 months.
| BIO | IRMD | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 58% | 1 day ago 81% |
| Stochastic ODDS (%) | 1 day ago 67% | 1 day ago 64% |
| Momentum ODDS (%) | 1 day ago 70% | 1 day ago 85% |
| MACD ODDS (%) | 1 day ago 62% | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 70% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 69% | 1 day ago 81% |
| Advances ODDS (%) | 4 days ago 68% | 4 days ago 72% |
| Declines ODDS (%) | 18 days ago 66% | 18 days ago 55% |
| BollingerBands ODDS (%) | 1 day ago 68% | 1 day ago 62% |
| Aroon ODDS (%) | 1 day ago 63% | 6 days ago 75% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| CGFCX | 77.36 | 1.08 | +1.42% |
| American Funds Growth Fund of Amer 529C | |||
| QSMRX | 23.59 | 0.05 | +0.21% |
| AQR Small Cap Momentum Style R6 | |||
| GSMYX | 24.85 | N/A | N/A |
| Goldman Sachs Small/Mid Cap Growth Instl | |||
| LAMQX | 26.16 | N/A | N/A |
| Lord Abbett Dividend Growth R2 | |||
| CECYX | 30.75 | N/A | N/A |
| Columbia Large Cap Enhanced Core Inst3 | |||
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.